- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04505826
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: There may be multiple sites in this clinical trial.
- Phone Number: (415) 651-7206
- Email: clinical@olema.com
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2109
- Macquarie University
-
Westmead, New South Wales, Australia, 2145
- Westmead
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- Icon Cancer Centre
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Cancer Research South Australia
-
-
-
-
California
-
Los Angeles, California, United States, 90404
- UCLA Hematology/Oncology
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Deerfield Beach, Florida, United States, 33442
- University of Miami, Sylvester Comprehensive Cancer Center
-
Orlando, Florida, United States, 32804
- Advent Health
-
Sarasota, Florida, United States, 34232
- Florida Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Saint Luke's Hospital of Kansas City
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
Portland, Oregon, United States, 97239
- OHSU Knight Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or metastatic disease
- Must not have received prior oral endocrine therapy < 2 weeks prior to first dose
- Must not have received prior, chemotherapy in 2 weeks or within 5 half-lives whichever is earlier, antibody therapy within 4 weeks or investigational therapy within 4 weeks or 5 half-lives whichever is earlier, prior to the first dose
- Adequate hepatic function
- Adequate renal function
- Normal coagulation panel
- Willingness to use effective contraception
Exclusion Criteria:
- Gastrointestinal disease
- Significant renal disease
- Significant cardiovascular disease
- Significant ECG abnormalities
- Ongoing systemic bacterial, fungal, or viral infection (requiring antimicrobial therapy)
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OP-1250 Phase I Part A (Dose Escalation) and Part B (Dose Expansion)
Phase I Part A will evaluate the safety and pharmacokinetics (PK)of a range of OP-1250 doses to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
Phase I Part B will evaluate the safety and PK of OP-1250 to confirm the RP2D dose.
|
Complete Estrogen Receptor ANtagonist (CERAN)
|
Experimental: OP-1250 Phase II
This portion of the study further explores the clinical activity, safety, and PK of OP-1250 monotherapy at the RP2D and will estimate preliminary anti-tumor efficacy in 3 cohorts. Cohort A will enroll subjects with measurable disease without evidence of CNS metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases. |
Complete Estrogen Receptor ANtagonist (CERAN)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicities (DLT)
Time Frame: The first 28 days of treatment
|
To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of OP-1250, the incidence of DLTs will be assessed.
|
The first 28 days of treatment
|
Characterize the incidence, nature and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250
Time Frame: Up to 42 days after end of treatment
|
Characterize the incidence, nature and severity of TEAEs and SAEs of OP-1250 according to NCI-CTCAE version 5.0
|
Up to 42 days after end of treatment
|
Pharmacokinetics of OP-1250
Time Frame: Every 28 days
|
Plasma concentrations of OP-1250 will be assessed at predefined intervals
|
Every 28 days
|
Anti-tumor activity of OP-1250
Time Frame: Every 8 weeks
|
Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines
|
Every 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mark Shilkrut, MD, Olema Pharmaceuticals, Inc.
- Study Director: Gurpreet Mathauda-Sahota, PharmD, Olema Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OP-1250-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone Receptor Positive Breast Carcinoma
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
BeiGeneRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...Australia, United States
-
Oana Danciu, MDPfizer; Big Ten Cancer Research ConsortiumActive, not recruitingMetastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive TumorUnited States
-
Laura Huppert, MD, BAAmbrx, Inc.Not yet recruitingARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerTriple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast CancerUnited States
-
SOLTI Breast Cancer Research GroupRadius Health, Inc.CompletedBreast Cancer | Hormone Receptor Positive Breast CarcinomaSpain
-
National Cancer Institute (NCI)TerminatedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor PositiveUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingInvasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor PositiveUnited States
-
Adrienne G. WaksEli Lilly and Company; Verastem, Inc.RecruitingBreast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast CancerUnited States
-
Jose Pablo LeoneEli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)RecruitingMale Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Negative Breast CarcinomaUnited States
Clinical Trials on OP-1250
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Olema Pharmaceuticals, Inc.PfizerRecruiting
-
International Medical UniversityKotra Pharma (M) Sdn BhdCompletedCancer of Breast | Cancer ColonMalaysia
-
Inje UniversityCompleted
-
Molnlycke Health Care ABCompleted
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Korea, Republic of
-
Federal University of Minas GeraisCompletedAttention Deficit and Disruptive Behavior Disorders | Motor Skills DisordersBrazil
-
University of ReginaCompletedDepression | Stress | Anxiety | Social IsolationCanada
-
Brugmann University HospitalCompletedPediatric Cardiac Surgery | TransfusionBelgium
-
The University of Texas Health Science Center,...RecruitingHypothermia; Anesthesia | Hypothermia, Newborn | Hypothermia, SequelaUnited States